The rheumatology therapeutics global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Rheumatology Therapeutics Market, 2024 report by The Business Research Company
offers comprehensive insights into the current state of the market and
highlights future growth opportunities.
Market Size -
The rheumatology therapeutics market size has grown steadily in recent years.
It will grow from $40.45 billion in 2023 to $42.40 billion in 2024 at a
compound annual growth rate (CAGR) of 4.8%. The growth in the historic period
can be attributed to the rising prevalence of rheumatologic disorders,
increasing the aging population globally, growing awareness about treatment
options, advancements in biological therapies, and expansion of healthcare
access in emerging markets.
The rheumatology therapeutics market size is expected to see steady growth in
the next few years. It will grow to $51.42 billion in 2028 at a compound annual
growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed
to the shift towards personalized medicine approaches, rising adoption of
biosimilars in rheumatology, increasing investment in research and development,
integration of digital health technologies, and regulatory approvals for novel
therapies. Major trends in the forecast period include growth in telemedicine
and remote monitoring solutions, expansion of targeted therapies for specific
rheumatic conditions, emphasis on patient-centric care models, expansion of
biologic treatments beyond monoclonal antibodies, and adoption of value-based
pricing models.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report
Scope Of Rheumatology Therapeutics Market
The Business Research Company's reports encompass a wide range of information,
including:
1. Market Size (Historic and Forecast): Analysis of the market's historical
performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market
landscape.
4. Key Segments: Breakdown of the market into its primary segments and their
respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and
geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting
the market.
Rheumatology Therapeutics Market Overview
Market Drivers -
The rising prevalence of autoimmune diseases is expected to propel the growth
of the rheumatology therapeutics market going forward. An autoimmune disease is
a condition where the immune system mistakenly attacks and damages the body's
tissues. The prevalence of autoimmune diseases is growing due to a combination
of genetic, environmental, and lifestyle factors, including increased awareness
and improved diagnostic capabilities. Rheumatology therapeutics are required
for autoimmune diseases to manage inflammation, alleviate symptoms, and prevent
joint and tissue damage caused by the immune system attacking the body. For
instance, in June 2024, according to the Australian Institute of Health and
Welfare, an Australia-based government agency, around 514,000 people in
Australia, or 2.0% of the population, were estimated to be living with
rheumatoid arthritis in 2022. Rheumatoid arthritis accounted for 2.0% of the
total disease burden and 16% of the burden for all musculoskeletal conditions
in 2023. Therefore, the rising prevalence of autoimmune diseases is driving the
growth of the rheumatology therapeutics market.
Market Trends -
Major companies operating in the rheumatology therapeutics market are
developing innovative solutions, such as intravenous (IV) formulations, to
enhance treatment efficacy and patient convenience. An intravenous (IV)
formulation refers to a medication or substance that is administered directly
into a vein through a needle or catheter. For instance, in October 2023,
Novartis AG, a Switzerland-based pharmaceutical company, announced that the US
Food and Drug Administration (FDA) had approved Cosentyx, an intravenous (IV)
formulation. This form of Cosentyx is uniquely approved to treat adults with
psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic
axial spondyloarthritis (nr-axSpA). It works by specifically targeting and
inhibiting interleukin-17A (IL-17A) and is the only non-tumor necrosis factor
alpha (TNF-α) IV treatment available for these conditions.
The rheumatology therapeutics market covered in this report is segmented –
1) By Drug Class: Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal
Anti-Inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Other Drugs Classes
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By Disease Indication: Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic
Arthritis, Ankylosing Spondylitis, Other Disease Indications
Get an inside scoop of the rheumatology therapeutics market, Request now for
Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=17246&type=smp
Regional Insights -
North America was the largest region in the rheumatology therapeutics market in
2023. Asia-Pacific is expected to be the fastest-growing region in the forecast
period. The regions covered in the rheumatology therapeutics market report are
Asia-Pacific, Western Europe, Eastern Europe, North America, South America,
Middle East, Africa.
Key Companies -
Major companies operating in the rheumatology therapeutics market are Pfizer
Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie
Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG,
Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc.,
Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Janssen Biotech,
Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals, UCB S.A.,
Galapagos NV (GLPG), Genentech Inc.
Table of Contents
1. Executive Summary
2. Rheumatology Therapeutics Market Report Structure
3. Rheumatology Therapeutics Market Trends And Strategies
4. Rheumatology Therapeutics Market – Macro Economic Scenario
5. Rheumatology Therapeutics Market Size And Growth
…..
27. Rheumatology Therapeutics Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model:
https://www.thebusinessresearchcompany.com/global-market-model
No comments:
Post a Comment